Literature DB >> 3142227

In vivo effects of aurothioglucose and sodium thioglucose on rat tissue sulfhydryl levels and plasma sulfhydryl reactivity.

M L Hu1, C J Dillard, A L Tappel.   

Abstract

The active component of aurothioglucose (ATG) in effecting changes in plasma sulfhydryl (SH) levels and plasma SH reactivity with 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) was determined. These two measurements are applied clinically to rheumatoid arthritis patients undergoing chrysotherapy. Normal rats were injected intramuscularly daily for seven days with 30 mumol of either ATG or sodium thioglucose (STG)/kg body wt or with an equivalent volume of the carrier, 0.05% benzyl alcohol. ATG but not STG significantly increased total SH levels in plasma, liver, and kidney. The seven-day treatment with ATG significantly increased glutathione levels in kidney but not in liver or plasma. Thus, gold(I) rather than thioglucose was the active moiety that affected SH levels in ATG-injected rats. In vivo, gold(I) was also the active moiety that stimulated plasma SH reactions with DTNB at pH 7.4, since injection of ATG but not STG stimulated the SH reactivity in fresh plasma. In vitro, ATG increased the rate of plasma reaction with DTNB at pH 7.4, thus, gold(I) ions acted as a catalyst in the SH-disulfide exchange reaction. This study demonstrates that gold(I) but not its thiol ligand strongly interacts with protein SH groups in the rat tissues. Such an interaction may play an important role in the biological actions of gold.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142227     DOI: 10.1007/bf01969104

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  24 in total

1.  Serum sulphydryl levels in rheumatoid patients treated with alclofenac.

Authors:  P H Evans
Journal:  Curr Med Res Opin       Date:  1975       Impact factor: 2.580

2.  Effect of anti-arthritic drugs on sulfhydryl reactivity of rat serum.

Authors:  D T Walz; M J DiMartino
Journal:  Proc Soc Exp Biol Med       Date:  1972-05

3.  Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent.

Authors:  J Sedlak; R H Lindsay
Journal:  Anal Biochem       Date:  1968-10-24       Impact factor: 3.365

4.  Abnormal sulfhydryl-disulfide interchange in serum of rats with adjuvant arthritis: correction by anti-inflammatory agents.

Authors:  M Buttler; T Giannina; D I Cargill; F Popick; B G Steinetz
Journal:  Proc Soc Exp Biol Med       Date:  1969-11

5.  Free thiomalate levels in patients with rheumatoid arthritis treated with disodium aurothiomalate: relationship to clinical outcome of therapy.

Authors:  S R Rudge; D Perrett; A J Swannell
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

6.  Serum sulfhydryl levels in rheumatoid patients treated with haloperidol.

Authors:  M G Grimaldi
Journal:  Scand J Rheumatol       Date:  1980       Impact factor: 3.641

7.  The influence of chrysotherapy on serum protein and immunoglobulin levels, rheumatoid factor, and antiepithelial antibody titers.

Authors:  N L Gottlieb; I M Kiem; N S Penneys; D R Schultz
Journal:  J Lab Clin Med       Date:  1975-12

8.  Alteration of thiol and superoxide dismutase status in rheumatoid arthritis treated with sulphasalazine.

Authors:  T Pullar; A Zoma; H A Capell; M F Khan; D H Brown; W E Smith
Journal:  Br J Rheumatol       Date:  1987-06

9.  Intracellular and extracellular sulphydryl levels in rheumatoid arthritis.

Authors:  J F Koster; P Biemond; A J Swaak
Journal:  Ann Rheum Dis       Date:  1986-01       Impact factor: 19.103

10.  Evaluation of the activity of rheumatoid arthritis. A comparative study on clinical symptoms and laboratory tests with special reference to serum sulfhydryl groups.

Authors:  M Haataja
Journal:  Scand J Rheumatol Suppl       Date:  1975
View more
  1 in total

1.  Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease.

Authors:  Ahmed Nadeem; Hanumanthrao Guru Raj; Sunil Kumar Chhabra
Journal:  Inflammation       Date:  2005-02       Impact factor: 4.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.